SCHEMBL4126098

SCHEMBL4126098

CN(Cc1cc(S(=O)(=O)c2cccnc2)n(-c2ccccc2Cl)n1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.39
SLC16A3 O15427 6/20 0.38
SLC16A1 P53985 5/20 0.38
KEAP1 Q14145 3/20 0.36
NFE2L2 Q16236 3/20 0.36
KDM4E B2RXH2 1/20 0.35
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
CNR1 P21554 2/20 0.34
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
NOX4 Q9NPH5 1/20 0.34
USP2 O75604 1/20 0.34
HSD11B1 P28845 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4123658 0.91 TAS2R14 (0.35) NAMPTKEAP1NFE2L2KDM4EHTT
SCHEMBL4125769 0.89 SLC16A3 (0.39) SLC16A3SLC16A1CNR1HTTNOX4
SCHEMBL4131429 0.89 KEAP1 (0.36) NAMPTKEAP1NFE2L2LMNAMAPT
SCHEMBL4131198 0.89 NAMPT (0.39) NAMPTSLC16A3SLC16A1KDM4ELMNA
SCHEMBL4135860 0.88 SLC16A3 (0.37) NAMPTSLC16A3SLC16A1MEN1KMT2A
SCHEMBL4126819 0.88 CNR1 (0.38) NAMPTSLC16A3SLC16A1CNR1HSD11B1
SCHEMBL4135426 0.87 NAMPT (0.36) NAMPTKEAP1NFE2L2HTTGPBAR1
SCHEMBL3702449 0.87 ALDH1A1 (0.44) NAMPTSLC16A3SLC16A1MEN1MAPT
SCHEMBL4130995 0.85 NAMPT (0.36) NAMPT
SCHEMBL4125804 0.85 NAMPT (0.36) NAMPTKEAP1NFE2L2MAPTGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 NAMPT 2129/4885SLC16A3 2809/4885SLC16A1 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.